This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waelti, E. Articles by Gimmi, C. D. Search for Related Content PubMed PubMed Citation Articles by Waelti, E. Articles by Gimmi, C. D.

Targeting HER-2/neu with Antirat Neu Virosomes for Cancer Therapy¹

Department of Clinical Research [W. N., S. R., W. A., W. C., C. D. G.], Institute of Pathology [W. E.], and Institute of Anatomy [R-R. B.], University of Bern, 3010 Bern, Switzerland

HER-2/neu (p185^HER2) oncogene represents an attractive target for antibody-mediated immunotherapy. The major problem of combining chemotherapy and immunotherapy is the severe side effects that limit the use of doxorubicin (Doxo) as a cytotoxic drug. We have used virosomes (Vir; reconstituted fusion-active viral envelopes) as a new drug delivery system and have shown that Vir are capable of binding and penetrating into tumor cells, delivering cytotoxic drugs. We have additionally demonstrated that conjugating Fab' fragments of an antirat Neu (anti-rNeu) monoclonal antibody to Vir selectively and efficiently inhibits tumor progression of established rNeu-overexpressing breast tumors. Fab'-Doxo-Vir combine the antiproliferative properties of the monoclonal antibody and the cytotoxic effect of Doxo in vivo. Furthermore, Fab'-Doxo-Vir significantly inhibit tumor formation at a tumor load representing metastatic spread. These results indicate that Vir conjugated with an antibody against a tumor antigen are a promising new selective drug delivery system for the treatment of tumors expressing a specific tumor antigen.

This article has been cited by other articles:

				G. Tuffin, E. Waelti, J. Huwyler, C. Hammer, and H.-P. Marti Immunoliposome Targeting to Mesangial Cells: A Promising Strategy for Specific Drug Delivery to the Kidney J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3295 - 3305. [Abstract] [Full Text] [PDF]

				M. Amacker, O. Engler, A. R. Kammer, S. Vadrucci, D. Oberholzer, A. Cerny, and R. Zurbriggen Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells Int. Immunol., June 1, 2005; 17(6): 695 - 704. [Abstract] [Full Text] [PDF]

				M. G. Cusi, M. T. Del Vecchio, C. Terrosi, G. G. Savellini, G. Di Genova, M. La Placa, F. Fallarino, C. Moser, C. Cardone, G. Giorgi, et al. Immune-Reconstituted Influenza Virosome Containing CD40L Gene Enhances the Immunological and Protective Activity of a Carcinoembryonic Antigen Anticancer Vaccine J. Immunol., June 1, 2005; 174(11): 7210 - 7216. [Abstract] [Full Text] [PDF]